AI-Powered Stock Analysis & Investment Research

Analyze over 5,500 stocks using cutting-edge AI tools. Get real-time market insights, deep company fundamentals, and smarter investment decisions.

Screener Image

Direct Access To the Stock market

Trending Investment Case Today

Stock-Card

LLY

+10.39%
Stock-Card

FTV

+10.54%
Stock-Card

LEA

+10.72%
Stock-Card

CSL

+11.08%
Stock-Card

CE

+9.95%
Stock-Card

HRI

+9.95%
Stock-Card

ZWS

+10.00%

How to find the best strategy for you ?

Card image cap

Value

Our factor investing score meticulously assesses the intrinsic value of each asset, providing invaluable insights into its potential for long-term growth.

Card image cap

Growth

With a keen focus on growth prospects, our factor investing score analyzes each asset's trajectory, offering strategic guidance for maximizing returns in dynamic market conditions..

Card image cap

Quality

With an emphasis on quality metrics, our factor investing score meticulously evaluates the fundamental strength and stability of each asset, safeguarding your portfolio against potential risks.

Card image cap

Volatility

By meticulously evaluating volatility, our factor investing score helps you navigate market turbulence, ensuring a balanced portfolio resilient to unpredictable fluctuations.

Card image cap

Momentum

Leveraging momentum analysis, our factor investing score identifies assets poised for upward trends, empowering you to capitalize on market momentum for optimized performance.

Card image cap

Yield

Focused on yield optimization, our factor investing score identifies assets with attractive income potential, enabling you to construct a diversified portfolio tailored to your income objectives.

Create a reliable strategy with the A-Score

Undervalued company with stable and reliable business like Warren Buffet

Get detailled Investment Case for more than 5500 Stocks

Image

Strong Company Updates

Get a complete corporate access : reliable, clear, and always available at the time you need it

Stock-Card
Earnings

AMD(AMD): AMD's Strong 2025 Results Set Stage for Continued Growth

Advanced Micro Devices, Inc. (AMD) reported record revenue of $34.6 billion for 2025, a 34% year-over-year increase, driven by strong growth in the data center and client segments. Gross margin was 52%, and earnings per share were $4.17, up 26% year over year. In the fourth quarter, revenue grew 34% year over year to $10.3 billion, with data center segment revenue increasing 39% to a record $5.4 billion. Earnings per share for the quarter came in at $1.53, beating estimates of $1.32.

550$ (-1.8%)

A-Score: 4.4/10

Feb -03
Stock-Card
Earnings

Mondelez(MDLZ): Mondelez's 2026 Outlook: Navigating Chocolate Market Resilience

Mondelez International reported an actual EPS of $0.68, slightly below estimates of $0.696. The company's revenue performance was in line with expectations, driven by its chocolate business, which showed resilience despite price increases. The gross margin was under pressure due to higher cocoa costs, but the company's pricing strategy and revenue growth management helped mitigate the impact. The EBIT margin was affected by increased investments behind brands, which is expected to drive future growth.

550$ (-1.8%)

A-Score: 5.6/10

Feb -03
Stock-Card
Earnings

Amgen(AMGN): Amgen's 2025 Earnings: A Strong Foundation for Future Growth

Amgen Inc. delivered a robust financial performance in 2025, with revenues and earnings per share (EPS) experiencing double-digit growth. The company's EPS came in at $5.29, beating analyst estimates of $4.73. The broad portfolio achieved record results, with 14 products reaching blockbuster status and 18 products achieving record results. Revenues were bolstered by strong sales across various products, including Repatha, Evenity, and Tezspire, which grew by more than 30% year over year. The biosimilar portfolio also delivered $3 billion in sales, a 37% increase, with PAV Blue, a biosimilar to EYLEA, reaching $700 million in sales.

550$ (-1.8%)

A-Score: 6.3/10

Feb -03
Register Now

Quality Equity Research. Easy Access

Get started with our cost-effective equity research

Monthly Annual Up to 30% Discount

Free Trial

FREE
7 Days
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Access to US Investment Case
  • API calls limited to 10/day
  • Request new coverage
  • Premium Support
Start Free Trial

Ultimate

$99.90
per month
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Unlimited access to Investment Case
  • API calls limited to 2500/minute
  • Request new coverage
  • Premium Support
Buy Now